Press Releases

Entasis Therapeutics to Present at the 39th Annual Cowen Healthcare Conference

March 6, 2019 at 4:01 PM EST

WALTHAM, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer, will present at the 39th Annual Cowen Healthcare Conference being held March 11-13, 2019 in Boston, Massachusetts.

Details of the presentations are below:
Event: 39th Annual Cowen Healthcare Conference
Date: March 11, 2019
Time: 2:50 – 3:20 PM ET

A live webcast of the presentation can be accessed under "Investors & Media" in the “News & Events” section of the Company's website at An archived replay of the webcast will be available on its website for 30 days after the conference.

In addition to his presentation, Dr. Perros will be hosting 1-on-1 investor meetings at the conference. Investors attending the conference who are interested in meeting with Company management should contact their Cowen representatives.

About Entasis
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis’ targeted-design platform has produced a pipeline of product candidates, including ETX2514SUL (targeting A. baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). For more information, visit

Entasis Company Contact    
Kyle Dow
Entasis Therapeutics
(781) 810-0114

Investor Relations Contact
Lee Roth
The Ruth Group

Media Contact
Kirsten Thomas
The Ruth Group
(508) 280-6592


Source: Entasis Therapeutics Holdings Inc.